Updated 07:15 GMT, 18 Nov 2026 SPX 7,340.53 -1.03% NDX 27,001.78 -0.72% VIX 25.46 +11.13% GOLD 3,772.20 -2.38% CL 83.98 -2.36% BTC 64,721.99 -0.26%
NAS100 27,002 −0.72% S&P 7,341 −1.03% GOLD $3,772 −2.38% BTC $64,722 −0.26% VIX 25.46 +11.13% latest tape · as of 07:15 UTC
The Screen · Healthcare · Medical Devices

Axogen, Inc.

AXGN · Nasdaq · USD · Market cap $3.3B · 622 employees

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide.

Not yet scored
55.37 USD

Price as of 17 Nov 2026Daily close, not a live quote

Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price55.37 USD at the 17 Nov 2026 close
  • Our value readOvervalued vs our fair value, as of 17 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenNot yet scored
  • OptionsOpen interest leans heavily to calls (put/call 0.04)
  • Last reviewed17 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $37.76 to $43.42, base estimate $37.76 (screen dated 2026-11-17).

Current read
Markup ?
Overvalued · screened 2026-11-17
  • Trend Markup
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.04, read 2026-11-17
  • Ethical screen not yet scored
Price55.37 USD
Fair value37.76
Ethical score70.0/100
Value readOvervaluedas of 17 Nov 2026
Our investment reviews on this name
2026-11-04Read Markup49.50+11.9% to today ✓Markdown gives way to Markup after a 32% rise in 3 weeks
2026-10-11Read Markdown37.39+48.1% to today Distribution gives way to Markdown after a 19% slide in 2 weeks
2026-09-24Read Distribution45.93+20.6% to today Accumulation gives way to Distribution with volume flow in agreement
2026-08-22Read Accumulation46.43+19.3% to today ✓Markdown gives way to Accumulation after an 8% rise in 7 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Axogen, Inc. holds its Markup at $55.37. The statistical read favours the buyers, held for 13 days.

As held on the ledger · 2026-11-17
PhaseMarkup
Quantitative stateThe statistical read favours the buyers, held for 13 days
Price at the screen$55.37
ValuationN/A trailing · 78.49 forward price to earnings
Values screenNot scored · score 70.0
Beta1.15
The Workings

Five Screens, Shown in Full

This security has not been fully scored against the values screen yet.

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 30.51% Below 33% Interest-bearing debt is just 30.5% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 2.70% Below 33% Cash held in interest-bearing accounts and securities is 2.7% of assets, under the one-third limit. Pass
Receivables 27.84% Below 49% Money owed to the company is 27.8% of assets, under the 49% limit. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

The Read, in Plain English

Axogen, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.

Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.

2026-10-25

Axogen, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.

2026-09-24 Clears

Axogen, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 31%, inside the ~33% line, and almost none of its income is interest, so it passes.

Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Overvalued vs our fair value, as of 17 Nov 2026: it trades above our $37.76 fair value estimate, 26.20% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

37.76Conservative37.76Base case43.42Growth case 55.37Price

Fair value range in USD, drawn from the 2026-11-17 screen. The gold marker is the market price at the same screen. The price runs 46.6% above the base estimate.

The Street's Range
56.00Street low 60.00Street average 65.00Street high 55.37Price

Third-party analyst targets: 11 covering, consensus Strong Buy. The average target sits +8% from the screen price.

Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.

Price History & Projections

Where our models see it going: fair-value estimate $37.76, with a range of $37.76 to $43.42, dated to the 2026-11-17 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Nerve graft growth still deep in the red

Picture a surgeon repairing a severed peripheral nerve with a processed allograft and you see Axogen's entire market. The company grows revenue at 27 percent yet still posts a negative 13 percent profit margin and negative 18 percent return on equity. Shares sit at 39.85 dollars, 17 percent above fair value, on a forward multiple of 54.7 times, which is why the opportunity rating is none despite clearing the ethical screen.

We pass because the valuation already prices in rapid profitability that the numbers have not delivered. An unknown moat and persistent cash burn leave little margin for the execution slips common in early-stage medtech. Analyst targets may cluster near 50 dollars but that consensus does not change the negative margin of safety.

Reimbursement pressure and slower hospital adoption could keep losses alive longer than expected. High multiples on unprofitable growth usually flag risk, not opportunity. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E78.5xexpensive even after accounting for its growth
EPS, trailing-0.63
EPS, forward0.71
Revenue growth+26.2%strong top-line growth
Profit margin-12.0%currently unprofitable
Return on equity-10.3%not currently earning a positive return on equity
FCF yield0.90%
Debt to equity3.92heavy leverage: higher risk if revenue softens
Current ratio12.02comfortably covers its short-term bills
Beta1.15moves a little more than the market
Short interest, float0.13%
52-week range23.00 - 59.72
Market cap$3.3B
Employees622

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

AXGN trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-18 Markup $55.37 +8.8% Entry 20

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.8% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 25% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (9 analysts) rates it strong buy, with a mean price target of $51.

2026-11-11 Markup $50.89 +2.8% Entry 19

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.8% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A. Technically it is holding around 25% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (9 analysts) rates it strong buy, with a mean price target of $51.

2026-11-04 Markup · changed $49.50 +35.7% Entry 18

The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 35.7% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (9 analysts) rates it strong buy, with a mean price target of $51.

2026-10-28 Markdown $36.48 +0.0% Entry 17

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (9 analysts) rates it strong buy, with a mean price target of $51. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-27 Markdown $36.48 +0.0% Entry 16

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (9 analysts) rates it strong buy, with a mean price target of $51. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-26 Markdown $36.48 +0.0% Entry 15

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 3% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (9 analysts) rates it strong buy, with a mean price target of $51. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-25 Markdown $36.48 +0.0% Entry 14

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 12% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (9 analysts) rates it strong buy, with a mean price target of $51. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-24 Markdown $36.48 +0.0% Entry 13

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 12% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (9 analysts) rates it strong buy, with a mean price target of $51. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-23 Markdown $36.48 +0.0% Entry 12

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 12% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (9 analysts) rates it strong buy, with a mean price target of $51. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-22 Markdown $36.48 +2.4% Entry 11

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 2.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 12% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 287%. Our forward projection puts the odds of a 10% gain over the next month near 48%. The street (9 analysts) rates it strong buy, with a mean price target of $51. It reported earnings in this window, a natural checkpoint for the thesis.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on AXGN

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in AXGN's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $40.79 +1.4% · $1,014 +1.4%
2 months $31.96 +29.4% · $1,294 +29.4%
3 months $31.76 +30.3% · $1,303 +30.3%
6 months $29.98 +38.0% · $1,380 +38.0%
1 year $10.68 +287.4% · $3,874 +287.4%
2 years $7.00 +491.0% · $5,910 +491.0%
3 years $9.30 +344.8% · $4,448 +344.8%
5 years $20.56 +101.2% · $2,012 +101.2%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever AXGN does next, these words stay.

Axogen, Inc. · AXGN · Markup · $55.37
Recorded 2026-11-17 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.